758 related articles for article (PubMed ID: 26923521)
1. Olfactory impairment predicts cognitive decline in early Parkinson's disease.
Fullard ME; Tran B; Xie SX; Toledo JB; Scordia C; Linder C; Purri R; Weintraub D; Duda JE; Chahine LM; Morley JF
Parkinsonism Relat Disord; 2016 Apr; 25():45-51. PubMed ID: 26923521
[TBL] [Abstract][Full Text] [Related]
2. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
[TBL] [Abstract][Full Text] [Related]
3. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM
Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
[TBL] [Abstract][Full Text] [Related]
5. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
[TBL] [Abstract][Full Text] [Related]
7. CSF Aβ
Ba M; Yu G; Kong M; Liang H; Yu L
Transl Neurodegener; 2018; 7():22. PubMed ID: 30338062
[TBL] [Abstract][Full Text] [Related]
8. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
[TBL] [Abstract][Full Text] [Related]
9. Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer's disease in patients with mild cognitive impairment: A 5-year follow-up study.
Yoon JH; Kim M; Moon SY; Yong SW; Hong JM
J Neurol Sci; 2015 Aug; 355(1-2):174-9. PubMed ID: 26076880
[TBL] [Abstract][Full Text] [Related]
10. Olfaction and taste in Parkinson's disease: the association with mild cognitive impairment and the single cognitive domain dysfunction.
Cecchini MP; Federico A; Zanini A; Mantovani E; Masala C; Tinazzi M; Tamburin S
J Neural Transm (Vienna); 2019 May; 126(5):585-595. PubMed ID: 30911822
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease: evolution of cognitive impairment and CSF Aβ
Lerche S; Wurster I; Röben B; Machetanz G; Zimmermann M; Bernhard F; Stransky E; Deuschle C; Schulte C; Hansson O; Zetterberg H; Gasser T; Berg D; Maetzler W; Brockmann K
J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):165-170. PubMed ID: 30254084
[TBL] [Abstract][Full Text] [Related]
12. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.
Shahid M; Kim J; Leaver K; Hendershott T; Zhu D; Cholerton B; Henderson VW; Tian L; Poston KL
Neurobiol Dis; 2019 Jul; 127():278-286. PubMed ID: 30826425
[TBL] [Abstract][Full Text] [Related]
13. CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease.
Terrelonge M; Marder KS; Weintraub D; Alcalay RN
J Mol Neurosci; 2016 Jan; 58(1):88-92. PubMed ID: 26330275
[TBL] [Abstract][Full Text] [Related]
14. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
15. CSF biomarker changes precede symptom onset of mild cognitive impairment.
Moghekar A; Li S; Lu Y; Li M; Wang MC; Albert M; O'Brien R;
Neurology; 2013 Nov; 81(20):1753-8. PubMed ID: 24132375
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
Wolfsgruber S; Polcher A; Koppara A; Kleineidam L; Frölich L; Peters O; Hüll M; Rüther E; Wiltfang J; Maier W; Kornhuber J; Lewczuk P; Jessen F; Wagner M
J Alzheimers Dis; 2017; 58(3):939-950. PubMed ID: 28527210
[TBL] [Abstract][Full Text] [Related]
17. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
[TBL] [Abstract][Full Text] [Related]
18. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
[TBL] [Abstract][Full Text] [Related]
19. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
[TBL] [Abstract][Full Text] [Related]
20. Correlation among olfactory function, motors' symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson's disease.
Masala C; Solla P; Liscia A; Defazio G; Saba L; Cannas A; Cavazzana A; Hummel T; Haehner A
J Neurol; 2018 Aug; 265(8):1764-1771. PubMed ID: 29804147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
